Condition: Gliomas Harboring IDH1 and/or IDH2 Mutations · Glioma Glioblastoma Multiforme · Glioma of Brainstem · Sponsor: Xiangya Hospital of Central South University
A vision-language model using preoperative MRI and clinical variables has been developed to simultaneously predict three key molecular markers in midline gliomas: H3K27M, IDH, and 1p/19q. This prospective multicenter study will validate the model's accuracy in preoperative molecular subtyping and its value in prognostic assessment and clinical decision-making across multiple neurosurgical centers.
This description comes directly from the study's public registry record.
Gong Xuan, MD. · 0086-731-8975-3037 · gong.xuan@csu.edu.cn
Shuwen Kuang, MD. · 0086-13367494221 · 228102171@csu.edu.cn
Always discuss trial participation with your own doctor first.
| Xiangya Hospital of Central South University | Changsha, Hunan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07608003